Evidence map›Paper›PMID 39679352›Full record

ArticleOpen forum infectious diseases2024

High Rates of High-risk HPV Anal Infection and Abnormal Cytology in a Cohort of Transgender People Assigned Male at Birth.

Omar Harfouch, Andrea Lisco, Habib Omari, Rahwa Eyasu, Ashley Davis, Meredith Zoltick, Emade Ebah, Amelia Cover, Phyllis Bijole, Rachel Silk and 9 more

Abstract read
In one paragraph

Article in Open forum infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Omar HarfouchInstitute of Human Virology at the University of Maryland Baltimore, Baltimore, Maryland, USA.ORCID https://orcid.org/0000-0002-0327-7772
Andrea LiscoNational Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA.ORCID https://orcid.org/0000-0002-1475-356X
Habib OmariInstitute of Human Virology at the University of Maryland Baltimore, Baltimore, Maryland, USA.
Rahwa EyasuInstitute of Human Virology at the University of Maryland Baltimore, Baltimore, Maryland, USA.
Ashley DavisInstitute of Human Virology at the University of Maryland Baltimore, Baltimore, Maryland, USA.
Meredith ZoltickInstitute of Human Virology at the University of Maryland Baltimore, Baltimore, Maryland, USA.
Emade EbahInstitute of Human Virology at the University of Maryland Baltimore, Baltimore, Maryland, USA.
Amelia CoverInstitute of Human Virology at the University of Maryland Baltimore, Baltimore, Maryland, USA.
Phyllis BijoleHIPS Org, Washington DC, USA.
Rachel SilkInstitute of Human Virology at the University of Maryland Baltimore, Baltimore, Maryland, USA.
David SternbergInstitute of Human Virology at the University of Maryland Baltimore, Baltimore, Maryland, USA.
Tina LiuCritical Care Medicine Department, National Institute of Health, Bethesda, Maryland, USA.
Grace GarrettCritical Care Medicine Department, National Institute of Health, Bethesda, Maryland, USA.
Miriam JonesHIPS Org, Washington DC, USA.
Randy KierHIPS Org, Washington DC, USA.
Henry MasurCritical Care Medicine Department, National Institute of Health, Bethesda, Maryland, USA.
Shyamasundaran KottililInstitute of Human Virology at the University of Maryland Baltimore, Baltimore, Maryland, USA.
Sarah KattakuzhyInstitute of Human Virology at the University of Maryland Baltimore, Baltimore, Maryland, USA.
Elana S RosenthalInstitute of Human Virology at the University of Maryland Baltimore, Baltimore, Maryland, USA.ORCID https://orcid.org/0000-0001-7234-4871

Funding

QAQC Johns Hopkins Institute for Clinical and Translational ResearchUL1TR003098 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2019 to 2023
$57.7M
NCATS NIH HHS UL1 TR003098NIAID NIH HHS HHSN272201300022CNIAID NIH HHS HHSN272201300022I
6 · The paper itself

Abstract

Background: Transgender people assigned male at birth (TG-AMAB) have higher rates of anal human papillomavirus (HPV) infection and anal cancer compared with cisgender populations. In a cohort of TG-AMAB in Washington DC, we determined the prevalence and epidemiological factors associated with anal high-risk HPV (HR-HPV) infection and cytological abnormalities. Methods: In an urban academic-community clinic, we recruited adults identifying as a gender different than their sex assigned at birth. Participants provided blood samples, anal swabs for HR-HPV and cytology, and completed surveys on sexual behaviors and use of gender-affirming hormones. Logistic regression was used to identify predictors of HR-HPV and abnormal cytology. Results: Of 97 TG, 80 were AMAB, of whom 66% were people with HIV (PWH); 73% tested positive for any anal HR-HPV, and 48% had abnormal cytology. Only 24% recalled HPV immunization. While TG-AMAB PWH had increased risk of HPV16 infection (37% vs 8%; Conclusions: TG-AMAB have a high prevalence of any HR-HPV and abnormal cytology, regardless of age, HIV status, or hormone use. Given high risk for anal cancer and low rates of HPV vaccination, there is a pressing need for primary and secondary anal cancer prevention strategies targeting this population.

Indexed as

gender-affirming hormonesHIVHPVtransgender people

Identifiers

PMID39679352
PMCPMC11639571

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.